ArticleBiopreservation and biobanking2019
Commentary on Improving Biospecimen Utilization by Classic Biobanks: Identifying Past and Minimizing Future Mistakes.
Article in Biopreservation and biobanking, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Current Assessment of Existing Biospecimen Use in Population-Based Cancer Research.Biopreservation and biobanking · 2026Article
- Stakeholder engagement to ensure the sustainability of biobanks: a survey of potential users of biobank services.European journal of human genetics : EJHG · 2022Article
- The Use of Human Tissues for Research: What Investigators Need to Know.Alternatives to laboratory animals : ATLA · 2022Article
- The Availability of Human Biospecimens to Support Biomarker Research.Biomarker insights · 2022Review
- Collaborating with a Graduate Marketing Class to Boost Awareness of the AIDS and Cancer Specimen Resource.Biopreservation and biobanking · 2021Article
- The Andalusian Registry of Donors for Biomedical Research: Five Years of History.Biotech (Basel (Switzerland)) · 2021Article
- Moving with the Times: The Health Science Alliance (HSA) Biobank, Pathway to Sustainability.Biomarker insights · 2021Article
- Opportunities and Risks for Research Biobanks in the COVID-19 Era and Beyond.Biopreservation and biobanking · 2020Review
- The Scale, Collections, and Biospecimen Distribution of Grade A Tertiary Hospital Biobanks in China: A National Survey.Frontiers in medicine · 2020Article
- Biobanking for Cancer Biomarker Research: Issues and Solutions.Biomarker insights · 2020Review
- Ensuring Effective Utilization of Biospecimens: Design, Marketing, and Other Important Approaches.Biopreservation and biobanking · 2019Article
- Biological, Medical, and Other Tissue Variables Affecting Biospecimen Utilization.Biopreservation and biobanking · 2019Article
- The Importance of Human Tissue Bioresources in Advancing Biomedical Research.Biopreservation and biobanking · 2019Article
- The Utilization of Biospecimens: Impact of the Choice of Biobanking Model.Biopreservation and biobanking · 2019Article
- Raising to the Challenge: Building a Federated Biobank to Accelerate Translational Research-The University Biobank Limburg.Frontiers in medicine · 2019Article
- Issues in the Use of Human Tissues to Support Precision Medicine.Journal of health care for the poor and underserved · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Many classic biobanks collect more human tissues than they distribute, leading to increased inventories, unnecessary storage, increased expenses, and reduced chargeback income. This situation is a result of biobanks operating without well-defined goals, having incorrect views of the potential number of investigators who will utilize specimens, and collection of biospecimens without adequately considering the need for specific tissues by investigators. These deficiencies frequently lead to unrealistic plans for biospecimen utilization and biobanks that are larger than necessary. For example, tissue collections usually are not periodically compared with biospecimen distribution and modified accordingly. An ethical issue has arisen as to the acceptability of consenting patients for the use of their tissues in research without a realistic planned approach to distribution of the biospecimens and their ultimate utilization in supporting biomedical research. These issues and how to minimize them are discussed in this commentary focused on how classic biobanks can improve utilization of their biospecimens.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.